The phase 2 study tested four doses of the glucagon-like peptide-1 receptor agonist among 626 participants, Pfizer said in a Dec. 1 news release.
After taking the pill twice a week for eight months, participants lost between 8% and 13% of their weight compared to the placebo. Among those who received the drug for 26 weeks, reductions in body weight ranged from 5% to 9.5%.
The most common side effects were nausea (with 73% reporting the adverse event), vomiting (47%) and diarrhea (25%). Pfizer said most adverse events were mild, and no serious safety risks were found. The discontinuation rates for the drug were higher than 50%, while the placebo’s discontinuation rate was about 40%.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
